Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 4/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | MAT2A | P31153 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 5/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | ACP1 | P24666 | 1/20 | 0.39 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
| ▸ | CASP1 | P29466 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16588906 | 0.91 | USP2 (0.40) | NPBWR1MCHR1MAT2AUSP2CYP1A2 | |
| SCHEMBL9954288 | 0.90 | OPRM1 (0.42) | USP2CYP1A2CYP3A4CREBBPMAPK1 | |
| SCHEMBL9954382 | 0.86 | NPBWR1 (0.44) | NPBWR1MCHR1CREBBPHIF1AOPRM1 | |
| SCHEMBL10035974 | 0.85 | NPBWR1 (0.41) | NPBWR1MCHR1CREBBPITGB1ITGA4 | |
| SCHEMBL9953587 | 0.83 | PPARG (0.41) | NPBWR1MCHR1MAT2AMEN1KMT2A | |
| SCHEMBL16588905 | 0.83 | USP2 (0.41) | NPBWR1MCHR1MAT2AUSP2CYP1A2 | |
| SCHEMBL9954533 | 0.81 | KCNA5 (0.42) | CREBBPMAPK1OPRM1OPRK1 | |
| SCHEMBL10036424 | 0.78 | NPBWR1 (0.40) | NPBWR1MEN1KMT2ATSHRHIF1A | |
| SCHEMBL15305627 | 0.78 | PTGS2 (0.48) | CREBBP | |
| SCHEMBL16748380 | 0.77 | MAT2A (0.36) | NPBWR1MCHR1MAT2ACREBBPMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2654752-B1 | DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS | PF MEDICAMENT (FR) | 2015-05-27 | — | — | EP | claimed |
| EP-2654752-A1 | DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS | Pierre Fabre Medicament (FR) | 2013-10-30 | — | — | EP | claimed |
| US-20130267520-A1 | DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS | PIERRE FABRE MEDICAMENT (FR) | 2013-10-10 | — | — | US | claimed |
| WO-2012085001-A1 | DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS | PIERRE FABRE MEDICAMENT (FR) | 2012-06-28 | — | — | WO | claimed |
| EP-2654752-B1 | DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS | PF MEDICAMENT (FR) | 2015-05-27 | — | — | EP | disclosed |
| US-8993569-B2 | Diarylpyridazinone derivatives, preparation thereof, and use thereof for the treatment of humans | PIERRE FABRE MEDICAMENT (FR) | 2015-03-31 | — | — | US | disclosed |
| US-8993569-B2 | Diarylpyridazinone derivatives, preparation thereof, and use thereof for the treatment of humans | PIERRE FABRE MEDICAMENT (FR) | 2015-03-31 | — | — | US | disclosed |
| US-8993569-B2 | Diarylpyridazinone derivatives, preparation thereof, and use thereof for the treatment of humans | PIERRE FABRE MEDICAMENT (FR) | 2015-03-31 | — | — | US | disclosed |
| EP-2654752-A1 | DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS | Pierre Fabre Medicament (FR) | 2013-10-30 | — | — | EP | disclosed |
| US-20130267520-A1 | DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS | PIERRE FABRE MEDICAMENT (FR) | 2013-10-10 | — | — | US | disclosed |
| US-20130267520-A1 | DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS | PIERRE FABRE MEDICAMENT (FR) | 2013-10-10 | — | — | US | disclosed |
| US-20130267520-A1 | DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS | PIERRE FABRE MEDICAMENT (FR) | 2013-10-10 | — | — | US | disclosed |
| WO-2012085001-A1 | DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS | PIERRE FABRE MEDICAMENT (FR) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267520-A1 | DIARYLPYRIDAZINONE DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF FOR THE TREATMENT OF HUMANS | KCNA4, KCNK4, KCNQ4 | NPBWR1 1692/4885MCHR1 2245/4885MAT2A 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.